Antiangiogenic agents and gastrointestinal cancers;Les antiangiogéniques en oncologie digestive

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 5 SUPPL. PART 1, 2008, Pages 504-520

  Lievre A ^a,b   Landi, B ^a   Mitry, E ^b   Taieb J ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEDIRANIB; ENDOSTATIN; FLUOROURACIL; IMC 1121 B; INFLIXIMAB; MONOCLONAL ANTIBODY IMC 1C11; PRINOMASTAT; SORAFENIB; SUNITINIB; TANOMASTAT; UNCLASSIFIED DRUG; VATALANIB;

ANGIOGENESIS; CANCER RESEARCH; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM HEMORRHAGE; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; PROTEINURIA; SHORT SURVEY; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANGIOGENESIS INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS;

EID: 50349083661     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2008.01.042     Document Type: Short Survey

References (116)

1. Folkman J., Merler E., Abernathy C., and Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133 (1971) 275-288
2. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
3. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9 (2003) 677-684
4. Senger D.R., Van de W.L., Brown L.F., Nagy J.A., Yeo K.T., Yeo T.K., et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12 (1993) 303-324
5. Karkkainen M.J., and Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19 (2000) 5598-5605
6. Jubb A.M., Oates A.J., Holden S., and Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6 (2006) 626-635
7. Cascinu S., Staccioli M.P., Gasparini G., Giordani P., Catalano V., Ghiselli R., et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6 (2000) 2803-2807
8. Inoue K., Ozeki Y., Suganuma T., Sugiura Y., and Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 79 (1997) 206-213
9. Ishigami S.I., Arii S., Furutani M., Niwano M., Harada T., Mizumoto M., et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78 (1998) 1379-1384
10. Itakura J., Ishiwata T., Friess H., Fujii H., Matsumoto Y., Buchler M.W., et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 3 (1997) 1309-1316
11. Jeng K.S., Sheen I.S., Wang Y.C., Gu S.L., Chu C.M., Shih S.C., et al. Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?. World J Gastroenterol 10 (2004) 676-681
12. Lord R.V., Park J.M., Wickramasinghe K., DeMeester S.R., Oberg S., Salonga D., et al. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 125 (2003) 246-253
13. Poon R.T., Ho J.W., Tong C.S., Lau C., Ng I.O., and Fan S.T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91 (2004) 1354-1360
14. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., and Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55 (1995) 3964-3968
15. Terris B., Scoazec J.Y., Rubbia L., Bregeaud L., Pepper M.S., Ruszniewski P., et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32 (1998) 133-138
16. Tokunaga T., Oshika Y., Abe Y., Ozeki Y., Sadahiro S., Kijima H., et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77 (1998) 998-1002
17. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
18. Warren R.S., Yuan H., Matli M.R., Gillett N.A., and Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95 (1995) 1789-1797
19. Margolin K., Gordon M.S., Holmgren E., Gaudreault J., Novotny W., Fyfe G., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19 (2001) 851-856
20. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
21. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
22. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., Heim W., Berlin J., Holmgren E., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508
23. Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J.T., Hecht J.R., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
24. Kabbinavar F.F., Hambleton J., Mass R.D., Hurwitz H.I., Bergsland E., and Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 3706-3712
25. Fuchs C., Marshall J., Mitchell E., Wierzbicki R., Ganju V., Jeffery M., et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: updated efficacy data. Proc Am Soc Clin Oncol 25 (2007) 4027 [abstract]
26. Kretzschmar A., Van Cutsem E., Michael M., Rivera F., Berry S., Di Bartolomeo M., et al. Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial. Proc Am Soc Clin Oncol 25 (2007) 4072 [abstract]
27. Kozloff M., Hainsworth J., Badarinath S., Cohn A., Flynn P.J., Dong W., et al. Survival of patients (pts) with mCRC treated with bevacizumab in combination with chemotherapy: pesults from the BRiTE registry. Gastrointestinal Cancers Symposium. Am Soc Clin Oncol 375 (2007) [abstract]
28. Hochster H.S., Hart L.L., Ramanathan R.K., Hainsworth J.D., Hedrick E.E., and Childs B.H. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. Proc Am Soc Clin Oncol 24 (2006) 3510 [abstract]
29. Saltz L., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Proc Am Soc Clin Oncol 25 (2007) 4028 [abstract]
30. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007) 1539-1544
31. Thésaurus. http://www.snfge.asso.fr/01-Bibliotheque/0G-Thesaurus-cancerologie/publication5/sommaire-thesaurus.asp.
32. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
33. Steward W.P., Thomas A., Morgan B., Wiedenmann B., Bartel C., Vanhoefer U., et al. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22 (2004) 3556 [abstract]
34. Hecht J., Trarbach T., Jaeger E., Hainsworth J., Wolff R., Lloyd K., et al. A randomized, double-bind, placebo-controlled, pahse III study in patients (pts) with metastatic adenocarcinoma of the colon and rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol 23 (2005) 3 [abstract]
35. Koehne C., Bajetta E., Lin E., Valle J., Van Cutsem E., Hecht J., et al. Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. Proc Am Soc Clin Oncol 25 (2007) 4033 [abstract]
36. Starling N., Cunningham D., Vazquez F., Hill P., Lechuga M.J., Brega N., et al. A phase I study of sunitinib in combination with FOLFIRI chemotherapy in treatment-naive, metastatic colorectal cancer. Gastrointestinal Cancers Symposium. JT>Am Soc Clin Oncol 319 (2007) [abstract]
37. Byrne A.T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J.I., et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9 (2003) 5721-5728
38. Frischer J.S., Huang J., Serur A., Kadenhe-Chiweshe A., McCrudden K.W., O'Toole K., et al. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol 25 (2004) 549-553
39. Dupont J., Schwartz L., Koutcher J., Spriggs D., Gordon M., Mendelson D., et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. Proc Am Soc Clin Oncol 22 (2004) 3009 [abstract]
40. Rixe O., Verslype C., Méric J.B., Tejpar S., Bloch J., Crabbe M., et al. Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors. Proc Am Soc Clin Oncol 24 (2006) 13161 [abstract]
41. Pavco P.A., Bouhana K.S., Gallegos A.M., Agrawal A., Blanchard K.S., Grimm S.L., et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 6 (2000) 2094-2103
42. Venook A., Hurwitz H., Cunningham C., Burris H.A., Aitchison R., Radka S., et al. Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: results of a phase II trial of a ribozyme targeting the pre-mRNA of VEGFR-1 (angiozyme), in combination with chemotherapy. Proc Am Soc Clin Oncol 22 (2003) 1025 [abstract]
43. Levine A.M., Quinn D.I., Gorospe G., Lenz H.J., and Tulpule A. Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies. Proc Am Soc Clin Oncol 22 (2004) 3008 [abstract]
44. Willett C.G., Kozin S.V., Duda D.G., di Tomaso E., Kozak K.R., Boucher Y., et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 33 (2006) S35-S40
45. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
46. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23 (2005) 8136-8139
47. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006) 1117-1128
48. Hwang Y.H., Choi J.Y., Kim S., Chung E.S., Kim T., Koh S.S., et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 29 (2004) 113-121
49. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., and Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27 (2007) 55-76
50. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
51. Llovet J., Ricci S., Mazzaferro V., Hilgard P., Raoul J., Zeuzem S., et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). Proc Am Soc Clin Oncol 25 (2007) LBA1 [abstract]
52. Faivre S., Raymond E., Douillard J., Boucher E., Lim H.Y., Kim J.S., et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 25 (2007) 3546 [abstract]
53. Zhu A.X., Sahani D.V., di Tomaso E., Duda D., Sindhwani V., Yoon S.S., et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol 25 (2007) 4637 [abstract]
54. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
55. Maki R.G., Fletcher J.A., Heinrich M.C., Morgan J.A., George S., Desai J., et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 23 (2005) 9011 [abstract]
56. Niedergethmann M., Hildenbrand R., Wostbrock B., Hartel M., Sturm J.W., Richter A., et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25 (2002) 122-129
57. Bockhorn M., Tsuzuki Y., Xu L., Frilling A., Broelsch C.E., and Fukumura D. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 9 (2003) 4221-4226
58. Fukasawa M., and Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 10 (2004) 3327-3332
59. Bruns C.J., Shrader M., Harbison M.T., Portera C., Solorzano C.C., Jauch K.W., et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102 (2002) 101-108
60. Crane C.H., Ellis L.M., Abbruzzese J.L., Amos C., Xiong H.Q., Ho L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 (2006) 1145-1151
61. Kindler H.L., Friberg G., Singh D.A., Locker G., Nattam S., Kozloff M., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040
62. Heinemann V., Wilke H., Mergenthaler H.G., Clemens M., Konig H., Illiger H.J., et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11 (2000) 1399-1403
63. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (2005) 3509-3516
64. Kindler H.L., Niedzwiecki D., Hollis D., Oraefo E., Schrag D., Hurwitz H., et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). Proc Am Soc Clin Oncol 25 (2007) 4508 [abstract]
65. Spano J., Chodkiewicz C., Maurel J., Wong R.P., Wasan H.S., Pithavala Y.K., et al. A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component. Proc Am Soc Clin Oncol 25 (2007) 4551 [abstract]
66. Wallace J.A., Locker G., Nattam S., Kasza K., Wade-Oliver K., Stadler W.M., et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium. Proc Am Soc Clin Oncol 25 (2007) 4608 [abstract]
67. Eccles S.A., Box G.M., Court W.J., Bone E.A., Thomas W., and Brown P.D. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56 (1996) 2815-2822
68. Watson S.A., Morris T.M., Collins H.M., Bawden L.J., Hawkins K., and Bone E.A. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br J Cancer 81 (1999) 19-23
69. Evans J.D., Stark A., Johnson C.D., Daniel F., Carmichael J., Buckels J., et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 85 (2001) 1865-1870
70. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., and Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87 (2002) 161-167
71. Bramhall S.R., Rosemurgy A., Brown P.D., Bowry C., and Buckels J.A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19 (2001) 3447-3455
72. Moore M.J., Hamm J., Dancey J., Eisenberg P.D., Dagenais M., Fields A., et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3296-3302
73. Konno H., Arai T., Tanaka T., Baba M., Matsumoto K., Kanai T., et al. Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Jpn J Cancer Res 89 (1998) 933-939
74. Yao J.C., Ng C., Hoff P.M., Phan A.T., Hess K., Chen H., et al. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. Proc Am Soc Clin Oncol 23 (2005) 4007 [abstract]
75. Kulke M., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). Proc Am Soc Clin Oncol 23 (2005) 4008 [abstract]
76. Hobday T.J., Rubin J., Holen K., Picus J., Donehower R., Marschke R., et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. Proc Am Soc Clin Oncol 25 (2007) 4504 [abstract]
77. Varker K.A., Campbell J., and Shah M.H. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 61 (2008) 661-668
78. Xu Y., Ellison C., Martin E., Young D., Campbell J., Vinci L., et al. A phase II study of thalidomide in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 20 (2002) 1931 [abstract]
79. Kulke M.H., Stuart K., Enzinger P.C., Ryan D.P., Clark J.W., Muzikansky A., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 (2006) 401-406
80. Kitadai Y., Haruma K., Tokutomi T., Tanaka S., Sumii K., Carvalho M., et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 4 (1998) 2195-2200
81. Shih C.H., Ozawa S., Ando N., Ueda M., and Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 6 (2000) 1161-1168
82. Uchida S., Shimada Y., Watanabe G., Tanaka H., Shibagaki I., Miyahara T., et al. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 77 (1998) 1704-1709
83. Auvinen M.I., Sihvo E.I., Ruohtula T., Salminen J.T., Koivistoinen A., Siivola P., et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 20 (2002) 2971-2979
84. Kamiya K., Konno H., Tanaka T., Baba M., Matsumoto K., Sakaguchi T., et al. Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody. Jpn J Cancer Res 90 (1999) 794-800
85. Kanai T., Konno H., Tanaka T., Baba M., Matsumoto K., Nakamura S., et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 77 (1998) 933-936
86. Matsumoto K., Konno H., Tanaka T., Baba M., Kanai T., Kamiya K., et al. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft. Jpn J Cancer Res 91 (2000) 748-752
87. Shah M.A., Ramanathan R.K., Ilson D.H., Levnor A., D'Adamo D., O'Reilly E., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24 (2006) 5201-5206
88. Enzinger P.C., Fidias P., Meyerhardt J., Stuart K., Fuchs C., Huberman M., et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Gastrointestinal Cancers Symposium. Am Soc Clin Oncol 68 (2006) [abstract]
89. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
90. Sane D.C., Anton L., and Brosnihan K.B. Angiogenic growth factors and hypertension. Angiogenesis 7 (2004) 193-201
91. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
92. Martel C.L., Presant C.A., Ebrahimi B., Upadhyaya G., Vakil M., Yeon C., et al. Bevacizumab-related toxicities: association of hypertension and proteinuria. Commun Oncol 3 (2006) 90-93
93. Scappaticci F.A., Skillings J.R., Holden S.N., Gerber H.P., Miller K., Kabbinavar F., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1239
94. Hambleton J., Skillings J., Kabbinavar F., Bergsland E., Holmgren E., Holden S.N., et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 23 (2005) 3554 [abstract]
95. Sugrue M., Yi J., Purdie D., Dong W., Grothey A., Kozloff M., et al. Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): Results from the BRiTE registry. Proc Am Soc Clin Oncol 25 (2007) 4136 [abstract]
96. Sugrue M., Kozloff M., Hainsworth J., Badarinath S., Cohn A., Flynn P., et al. Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: Results from the BRiTE registry. Gastrointestinal Cancers Symposium. Am Soc Clin Oncol 345 (2007) [abstract]
97. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
98. Hambleton J., Novotny W.F., Hurwitz H., Fehrenbacher L., Cartwright T., Hainsworth J., et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Proc Am Soc Clin Oncol 22 (2004) 3528 [abstract]
99. Drevs J., Siegert P., Medinger M., Mross K., Strecker R., Zirrgiebel U., et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25 (2007) 3045-3054
100. Eskens F.A., Planting A., Van Doorn L., Isoe T., Hayashi K., Hussain S., et al. An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors. Proc Am Soc Clin Oncol 24 (2006) 2034
101. Rini B.I., George D.J., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 24 (2006) 4522
102. Scappaticci F.A., Fehrenbacher L., Cartwright T., Hainsworth J.D., Heim W., Berlin J., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
103. Kesmodel S.B., Ellis L.M., Lin E., Chang G.J., Abdalla E.K., Kopetz S., et al. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. Gastrointestinal Cancers Symposium. Am Soc Clin Oncol 234 (2007) [abstract]
104. Kretzschmar A., Cunningham D., Berry S., Michael M., Di Bartolomeo M., Rivera F., et al. Feasibility of metastasectomy in patients treated with first-line bevacizumab for mCRC: Preliminary results from the First BEAT study. Gastrointestinal Cancers Symposium. Am Soc Clin Oncol 343 (2007) [abstract].
105. Gordon M.S., and Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 Suppl. 3 (2005) 25-33
106. Berry S., Michael M., Kretzschmar A., Cunningham D., Di Bartolomeo M., and Rivera F. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: preliminary results from first BEAT. Gastrointestinal Cancers Symposium. Am Soc Clin Oncol 245 (2006) [abstract]
107. Sugrue M., Kozloff M., Hainsworth J., Badarinath S., Cohn A., Flynn P., et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. Proc Am Soc Clin Oncol 24 (2006) 3535 [abstract]
108. Wright J.D., Secord A.A., Numnum T.M., Rocconi R.P., Powell M.A., Berchuck A., et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer (2007)
109. Robert C. Cutaneous side effects of antiangiogenic agents. Bull Cancer 94 Spec No (2007) S260-S264
110. Wolter P., Dumez H., and Schoffski P. Sunitinib and hypothyroidism. N Engl J Med 356 (2007) 1580-1581
111. Eskens F.A., and Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42 (2006) 3127-3139
112. Glusker P., Recht L., and Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354 (2006) 980-982
113. Martin G., Bellido L., and Cruz J.J. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25 (2007) 3559
114. Fakih M.G., and Lombardo J.C. Bevacizumab-induced nasal septum perforation. Oncologist 11 (2006) 85-86
115. Malka D., Van den E.M., Boige V., Dromain C., and Ducreux M. Splenic infarction and bevacizumab. Lancet Oncol 7 (2006) 1038
116. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 (2006) 24-40